Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. Lin Y, et al. Among authors: weisel k. Lancet Oncol. 2024 May 28:S1470-2045(24)00094-9. doi: 10.1016/S1470-2045(24)00094-9. Online ahead of print. Lancet Oncol. 2024. PMID: 38821074 Review.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Baertsch MA, Maclachlan KH, Chojnacka M, Diamond BT, John L, Reichert P, Huhn S, Blaney P, Gagler DC, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies FE, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani SZ, Landgren O, Raab MS, Weinhold N, Maura F. Cirrincione AM, et al. Among authors: weisel kc. Blood. 2024 May 10:blood.2024024299. doi: 10.1182/blood.2024024299. Online ahead of print. Blood. 2024. PMID: 38728430
Support after return to alcohol use: a mixed-methods study on how abstinence motivation and app use change after return to alcohol use in an app-based aftercare intervention for individuals with alcohol use disorder.
Lang C, Weisel KK, Saur S, Fuhrmann LM, Schoenleber A, Reichl D, Enewoldsen N, Steins-Loeber S, Berking M. Lang C, et al. Among authors: weisel kk. Addict Sci Clin Pract. 2024 May 6;19(1):35. doi: 10.1186/s13722-024-00457-7. Addict Sci Clin Pract. 2024. PMID: 38711152 Free PMC article. Clinical Trial.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: weisel k. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
Efficacy of an Internet- and Mobile-Based Intervention for Subclinical Anxiety and Depression (ICare Prevent) with Two Guidance Formats: Results from a Three-Armed Randomized Controlled Trial.
Zarski AC, Weisel KK, Berger T, Krieger T, Schaub MP, Berking M, Görlich D, Jacobi C, Ebert DD. Zarski AC, et al. Among authors: weisel kk. Psychother Psychosom. 2024 Apr 30:1-14. doi: 10.1159/000536149. Online ahead of print. Psychother Psychosom. 2024. PMID: 38688243 Free article.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Suvannasankha A, Bahlis N, Trudel S, Weisel K, Koenecke C, Oriol A, Voorhees PM, Alonso AA, Callander NS, Mateos MV, Reddy N, Hakim S, LaMacchia J, Patel N, Williams D, Jewell RC, Zhou X, Gupta I, Opalinska J, Nooka AK. Suvannasankha A, et al. Among authors: weisel k. Cancer. 2024 Apr 17. doi: 10.1002/cncr.35319. Online ahead of print. Cancer. 2024. PMID: 38630908
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, Scheid C, Hose D, Seckinger A, Luntz S, Besemer B, Munder M, Brossart P, Glass B, Lindemann HW, Weisel K, Hanoun C, Schnitzler P, Klemm S, Goldschmidt H, Raab M, Elmaagacli A. Salwender H, et al. Among authors: weisel k. Hematology. 2024 Dec;29(1):2320006. doi: 10.1080/16078454.2024.2320006. Epub 2024 Feb 26. Hematology. 2024. PMID: 38407192 Clinical Trial.
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Einsele H, et al. Among authors: weisel k. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24. Adv Ther. 2024. PMID: 38402374 Free PMC article.
292 results